Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 3848409, 12 pages
http://dx.doi.org/10.1155/2016/3848409
Research Article

Conifer Green Needle Complex in Patients with Precancerous Gastric Lesions: An Observational Pilot Study

1Laboratory of Cancer Chemoprevention and Oncopharmacology, N. N. Petrov Research Institute of Oncology, Ministry of Healthcare and Social Development, Saint Petersburg, Russia
2Department of Endoscopy, N. N. Petrov Research Institute of Oncology, Ministry of Healthcare and Social Development, Saint Petersburg, Russia
3Laboratory of Pathological Morphology, N. N. Petrov Research Institute of Oncology, Ministry of Healthcare and Social Development, Saint Petersburg, Russia
4Laboratory of Biochemistry, N. N. Petrov Research Institute of Oncology, Ministry of Healthcare and Social Development, Saint Petersburg, Russia
5Solagran Limited, Biotechnology Company, 98-106 Moray St., South Melbourne, VIC 3205, Australia
6Saint Petersburg State Forest Technical Academy, Saint Petersburg, Russia

Received 11 March 2016; Revised 25 October 2016; Accepted 27 October 2016

Academic Editor: Toku Takahashi

Copyright © 2016 Vladimir Bespalov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. Helicobacter pylori infection is common and can lead to precancerous gastric lesions. Standard antibiotic therapy has a failure rate of more than 25% from antibiotic resistance. The primary aim of this observational pilot study was to test the feasibility of a large-scale clinical trial of Conifer Green Needle Complex (CGNC) to treat precancerous gastric lesions. Secondary aims were to investigate H. pylori infection, stomach function, and histopathology of the gastric mucosa. Methods. A tablet form of CGNC (extracted from Pinus sylvestris and Picea abies (L) Karst) was prescribed to 26 patients with precancerous gastric lesions (two tablets, 100 mg CGNC/tablet, three times per day for six months). Another 24 patients received no treatment. Results. Compared with control patients, CGNC-treated patients showed total or partial regression (using the quantitative Rome III diagnostic criteria) of dyspeptic symptoms (92.3%, ), eradication of H. pylori infection (57.1%, ), a reduction in endoscopic signs of gastritis (92.3%, ), an increase of pepsinogen-pepsin in the gastric juice (57.7%, ), and total regression or reduction in the degree of intestinal metaplasia (46.2%, ) and lymphoplasmacytic infiltration (53.8%, ). Conclusions. This study justifies a randomised-controlled trial with CGNC in patients with atrophic gastritis.